Comparison of Cervical Cancer Screening with Single Test (HPV DNA Test) Versus Double Tests (HPV DNA Test with VIA/VILI)

Aims and Objectives To compare the diagnostic accuracy of single test (HPV DNA) with double tests (HPV DNA and VIA/VILI) for cervical cancer screening. Materials and Methods This hospital-based cross-sectional study was carried out on 256 women aged between 30 and 65 years. All women underwent HPV DNA test followed by VIA/VILI test and colposcopy. Colposcopic-guided biopsy was performed in 35 women with Reids score 3 and above. Diagnostic accuracy of HPV, VIA and VILI tests was calculated taking colposcopy and HPE reports as gold standard. The diagnostic tests included sensitivity, specificity, PPV and NPV, and kappa statistics was applied to find agreement levels among various tests. Results Pre-invasive lesions were significantly more common in lower socioeconomic group of women. HPV DNA test was positive in 8.5%, VIA in 19.5% and VILI in 15.2% of women. The agreement level was fair between HPV and VIA (k = 0.34), moderate between HPV and VILI (k = 0.51) and good between VIA and VILI (k = 0.79). HPV DNA test had significantly high specificity while VIA/VILI was more sensitive tests. There was no statistically significant difference in diagnostic accuracy of HPV test alone or with VIA/VILI. Conclusion Addition of VIA and VILI does not increase the diagnostic accuracy of HPV DNA test for cervical cancer screening.